Last reviewed · How we verify
NCT04649372: VECTOR
EndoVE endosCopic Treatment for Oesophageal and Gastric canceR
NA trial testing EndoVE in Oesophageal Cancer in 30 participants. Completed in 20 July 2022.
20 July 2022
Quick facts
| Lead sponsor | Mirai Medical |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 13 January 2021 |
| Primary completion | 20 July 2022 |
| Estimated completion | 20 July 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- EndoVE
Conditions studied
- Oesophageal Cancer — all drugs for Oesophageal Cancer →
- Oesophageal Disease — all drugs for Oesophageal Disease →
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Mirai Medical — full company profile →
Who can join
18 and older, any sex, with Oesophageal Cancer or Oesophageal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project aims to establish the safety and efficacy of treating patients with inoperable oesophageal cancer or gastric cancer, using an endoscopic electroporation system (EndoVE) to facilitate direct chemotherapy tumour absorption.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical Applications and Immunological Aspects of Electroporation-Based Therapies.
Luz JCDSD, Antunes F, Clavijo-Salomon MA, Signori E, et al · · 2021 · cited 14× · PMID 34358144 · DOI 10.3390/vaccines9070727 -
Electrochemotherapy of Primary Colon Rectum Cancer and Local Recurrence: Case Report and Prospective Analysis.
Rega D, Granata V, Petrillo A, Pace U, et al · · 2022 · cited 9× · PMID 35628872 · DOI 10.3390/jcm11102745
Verify or expand the search:
- PubMed search for NCT04649372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oesophageal Cancer
Currently open trials in the same condition.
- NCT06906887 — PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer · Phase 2 · recruiting
- NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
- NCT06364553 — Esophageal Self-expandable Metal Stent for Malignant Strictures: a Safety and Efficacy Study · NA · recruiting
- NCT06440174 — Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients with Oesophageal Cancer (VALUE) · recruiting
- NCT06212700 — PRIORITY-CONNECT 2 Pilot Trial · NA · recruiting
Other Mirai Medical trials
Trials by the same sponsor.
- NCT04929912 — Electroporation for Cancer Treatment Real World Registry · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04649372 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mirai Medical
- Last refreshed: 21 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04649372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing